The Experts below are selected from a list of 180 Experts worldwide ranked by ideXlab platform

B. Bok - One of the best experts on this subject based on the ideXlab platform.

  • reversibility of thyroid dysfunction induced by Recombinant Alpha Interferon in chronic hepatitis c
    Clinical Endocrinology, 1993
    Co-Authors: Eric Baudin, Patrick Marcellin, M Pouteau, Jean-pierre Benhamou, Catherine Lemmonier, Nicole Colaslinhart, Jeanpierre Le Floch, B. Bok
    Abstract:

    Summary OBJECTIVE Thyroid dysfunction has been reported as a complication of Interferon therapy. The aim of our study was to assess the risk factors and reversibility of thyroid disorders induced by Interferon therapy. DESIGN Prospective study. PATIENTS A series of 68 patients with chronic hepatitis C completed a therapeutic trial of Interferon Alpha 2b (IFN), randomized for dose adaptation, lasting for 24 weeks. MEASUREMENTS TSH and autoantibodies against thyroid were looked for at (- 2) weeks and 24 weeks in all patients. Blood samples obtained at (-2), 12, and 24 weeks were stored for additional hormonal studies in patients who developed thyroid dysfunction. Such patients with thyroid dysfunction were followed up for at least one year. RESULTS Only one out of 68 patients had abnormal TSH levels, and two had thyroid autoantibodies prior to Interferon therapy. Eight patients (12%) developed thyroid dysfunction (five hypothyroidism and three hyperthyroidism) during treatment. In four patients (all of them with thyroid dysfunction, P< 0-001) antimicrosomal, antithyro-globulin, and/or anti-TSH receptor antibodies appeared during Interferon therapy. All patients recovered normal thyroid function within 15 years after Interferon withdrawal. No pretreatment risk factor was identified. The patients with thyroid dysfunction did not significantly differ from the others as regards the dose of Interferon they received or the rate of normalization of transaminases. CONCLUSION (i) A 12% incidence of thyroid dysfunction was observed under Interferon therapy: (ii) secondary appearance under Interferon therapy of elevated thyroid autoantibodies was a risk factor; (iii) the thyroid disorders induced by Interferon were reversible.

  • Reversibility of thyroid dysfunction induced by Recombinant Alpha Interferon in chronic hepatitis C.
    Clinical endocrinology, 1993
    Co-Authors: Eric Baudin, Patrick Marcellin, M Pouteau, Jean-pierre Benhamou, Nicole Colas-linhart, Jean‐pierre Le Floch, Catherine Lemmonier, B. Bok
    Abstract:

    Thyroid dysfunction has been reported as a complication of Interferon therapy. The aim of our study was to assess the risk factors and reversibility of thyroid disorders induced by Interferon therapy. Prospective study. A series of 68 patients with chronic hepatitis C completed a therapeutic trial of Interferon Alpha 2b (IFN), randomized for dose adaptation, lasting for 24 weeks. TSH and autoantibodies against thyroid were looked for at (-2) weeks and 24 weeks in all patients. Blood samples obtained at (-2), 12, and 24 weeks were stored for additional hormonal studies in patients who developed thyroid dysfunction. Such patients with thyroid dysfunction were followed up for at least one year. Only one out of 68 patients had abnormal TSH levels, and two had thyroid autoantibodies prior to Interferon therapy. Eight patients (12%) developed thyroid dysfunction (five hypothyroidism and three hyperthyroidism) during treatment. In four patients (all of them with thyroid dysfunction, P < 0.001) antimicrosomal, antithyroglobulin, and/or anti-TSH receptor antibodies appeared during Interferon therapy. All patients recovered normal thyroid function within 1.5 years after Interferon withdrawal. No pretreatment risk factor was identified. The patients with thyroid dysfunction did not significantly differ from the others as regards the dose of Interferon they received or the rate of normalization of transaminases. (i) A 12% incidence of thyroid dysfunction was observed under Interferon therapy; (ii) secondary appearance under Interferon therapy of elevated thyroid autoantibodies was a risk factor; (iii) the thyroid disorders induced by Interferon were reversible.

  • Sustained hypothyroidism induced by Recombinant Alpha Interferon in patients with chronic hepatitis C.
    Gut, 1992
    Co-Authors: Patrick Marcellin, M Pouteau, P. Renard, J M Grynblat, N Colas Linhart, P Bardet, B. Bok, Jean-pierre Benhamou
    Abstract:

    Thyroid dysfunction has been reported in patients with malignant disease treated with Recombinant Alpha Interferon. Two cases of hypothyroidism in patients with chronic hepatitis C treated with Recombinant Alpha Interferon are reported. In one patient, Interferon induced hypothyroidism in the absence of pre-existing thyroid dysfunction and in the other it aggravated a pre-existing thyroid dysfunction. Both patients developed a severe, sustained hypothyroidism requiring thyroxine treatment for one year or more after stopping Alpha Interferon. Diagnosis of hypothyroidism during treatment can be difficult because of the common side effects of Alpha Interferon. Thyroid function should be assessed before and during Alpha Interferon therapy in patients with chronic hepatitis C.

Jean-pierre Benhamou - One of the best experts on this subject based on the ideXlab platform.

  • reversibility of thyroid dysfunction induced by Recombinant Alpha Interferon in chronic hepatitis c
    Clinical Endocrinology, 1993
    Co-Authors: Eric Baudin, Patrick Marcellin, M Pouteau, Jean-pierre Benhamou, Catherine Lemmonier, Nicole Colaslinhart, Jeanpierre Le Floch, B. Bok
    Abstract:

    Summary OBJECTIVE Thyroid dysfunction has been reported as a complication of Interferon therapy. The aim of our study was to assess the risk factors and reversibility of thyroid disorders induced by Interferon therapy. DESIGN Prospective study. PATIENTS A series of 68 patients with chronic hepatitis C completed a therapeutic trial of Interferon Alpha 2b (IFN), randomized for dose adaptation, lasting for 24 weeks. MEASUREMENTS TSH and autoantibodies against thyroid were looked for at (- 2) weeks and 24 weeks in all patients. Blood samples obtained at (-2), 12, and 24 weeks were stored for additional hormonal studies in patients who developed thyroid dysfunction. Such patients with thyroid dysfunction were followed up for at least one year. RESULTS Only one out of 68 patients had abnormal TSH levels, and two had thyroid autoantibodies prior to Interferon therapy. Eight patients (12%) developed thyroid dysfunction (five hypothyroidism and three hyperthyroidism) during treatment. In four patients (all of them with thyroid dysfunction, P< 0-001) antimicrosomal, antithyro-globulin, and/or anti-TSH receptor antibodies appeared during Interferon therapy. All patients recovered normal thyroid function within 15 years after Interferon withdrawal. No pretreatment risk factor was identified. The patients with thyroid dysfunction did not significantly differ from the others as regards the dose of Interferon they received or the rate of normalization of transaminases. CONCLUSION (i) A 12% incidence of thyroid dysfunction was observed under Interferon therapy: (ii) secondary appearance under Interferon therapy of elevated thyroid autoantibodies was a risk factor; (iii) the thyroid disorders induced by Interferon were reversible.

  • Reversibility of thyroid dysfunction induced by Recombinant Alpha Interferon in chronic hepatitis C.
    Clinical endocrinology, 1993
    Co-Authors: Eric Baudin, Patrick Marcellin, M Pouteau, Jean-pierre Benhamou, Nicole Colas-linhart, Jean‐pierre Le Floch, Catherine Lemmonier, B. Bok
    Abstract:

    Thyroid dysfunction has been reported as a complication of Interferon therapy. The aim of our study was to assess the risk factors and reversibility of thyroid disorders induced by Interferon therapy. Prospective study. A series of 68 patients with chronic hepatitis C completed a therapeutic trial of Interferon Alpha 2b (IFN), randomized for dose adaptation, lasting for 24 weeks. TSH and autoantibodies against thyroid were looked for at (-2) weeks and 24 weeks in all patients. Blood samples obtained at (-2), 12, and 24 weeks were stored for additional hormonal studies in patients who developed thyroid dysfunction. Such patients with thyroid dysfunction were followed up for at least one year. Only one out of 68 patients had abnormal TSH levels, and two had thyroid autoantibodies prior to Interferon therapy. Eight patients (12%) developed thyroid dysfunction (five hypothyroidism and three hyperthyroidism) during treatment. In four patients (all of them with thyroid dysfunction, P < 0.001) antimicrosomal, antithyroglobulin, and/or anti-TSH receptor antibodies appeared during Interferon therapy. All patients recovered normal thyroid function within 1.5 years after Interferon withdrawal. No pretreatment risk factor was identified. The patients with thyroid dysfunction did not significantly differ from the others as regards the dose of Interferon they received or the rate of normalization of transaminases. (i) A 12% incidence of thyroid dysfunction was observed under Interferon therapy; (ii) secondary appearance under Interferon therapy of elevated thyroid autoantibodies was a risk factor; (iii) the thyroid disorders induced by Interferon were reversible.

  • Recombinant Alpha Interferon for chronic hepatitis B in anti-HIV positive patients receiving zidovudine.
    Gut, 1993
    Co-Authors: Patrick Marcellin, N Boyer, J F Colin, M Martinot-peignoux, V Lefort, S Matheron, S Erlinger, Jean-pierre Benhamou
    Abstract:

    In this pilot study of the effects of Interferon alfa in 10 anti-HIV positive, chronic hepatitis B patients treated with zidovudine (AZT), tolerance to Interferon was good and similar to that in anti-HIV negative patients. After treatment, the HIV stage and CD4 lymphocyte count were unchanged. In two patients hepatitis B virus (HBV)-DNA and hepatitis B e antigen (HBeAg) disappeared and the serum alanine aminotransferase (ALT) returned to normal; loss of hepatitis B surface antigen (HBsAg) with absence of histopathological activity was observed after treatment in one of these patients. These preliminary results need to be confirmed by a larger study.

  • Sustained hypothyroidism induced by Recombinant Alpha Interferon in patients with chronic hepatitis C.
    Gut, 1992
    Co-Authors: Patrick Marcellin, M Pouteau, P. Renard, J M Grynblat, N Colas Linhart, P Bardet, B. Bok, Jean-pierre Benhamou
    Abstract:

    Thyroid dysfunction has been reported in patients with malignant disease treated with Recombinant Alpha Interferon. Two cases of hypothyroidism in patients with chronic hepatitis C treated with Recombinant Alpha Interferon are reported. In one patient, Interferon induced hypothyroidism in the absence of pre-existing thyroid dysfunction and in the other it aggravated a pre-existing thyroid dysfunction. Both patients developed a severe, sustained hypothyroidism requiring thyroxine treatment for one year or more after stopping Alpha Interferon. Diagnosis of hypothyroidism during treatment can be difficult because of the common side effects of Alpha Interferon. Thyroid function should be assessed before and during Alpha Interferon therapy in patients with chronic hepatitis C.

Patrick Marcellin - One of the best experts on this subject based on the ideXlab platform.

  • reversibility of thyroid dysfunction induced by Recombinant Alpha Interferon in chronic hepatitis c
    Clinical Endocrinology, 1993
    Co-Authors: Eric Baudin, Patrick Marcellin, M Pouteau, Jean-pierre Benhamou, Catherine Lemmonier, Nicole Colaslinhart, Jeanpierre Le Floch, B. Bok
    Abstract:

    Summary OBJECTIVE Thyroid dysfunction has been reported as a complication of Interferon therapy. The aim of our study was to assess the risk factors and reversibility of thyroid disorders induced by Interferon therapy. DESIGN Prospective study. PATIENTS A series of 68 patients with chronic hepatitis C completed a therapeutic trial of Interferon Alpha 2b (IFN), randomized for dose adaptation, lasting for 24 weeks. MEASUREMENTS TSH and autoantibodies against thyroid were looked for at (- 2) weeks and 24 weeks in all patients. Blood samples obtained at (-2), 12, and 24 weeks were stored for additional hormonal studies in patients who developed thyroid dysfunction. Such patients with thyroid dysfunction were followed up for at least one year. RESULTS Only one out of 68 patients had abnormal TSH levels, and two had thyroid autoantibodies prior to Interferon therapy. Eight patients (12%) developed thyroid dysfunction (five hypothyroidism and three hyperthyroidism) during treatment. In four patients (all of them with thyroid dysfunction, P< 0-001) antimicrosomal, antithyro-globulin, and/or anti-TSH receptor antibodies appeared during Interferon therapy. All patients recovered normal thyroid function within 15 years after Interferon withdrawal. No pretreatment risk factor was identified. The patients with thyroid dysfunction did not significantly differ from the others as regards the dose of Interferon they received or the rate of normalization of transaminases. CONCLUSION (i) A 12% incidence of thyroid dysfunction was observed under Interferon therapy: (ii) secondary appearance under Interferon therapy of elevated thyroid autoantibodies was a risk factor; (iii) the thyroid disorders induced by Interferon were reversible.

  • Reversibility of thyroid dysfunction induced by Recombinant Alpha Interferon in chronic hepatitis C.
    Clinical endocrinology, 1993
    Co-Authors: Eric Baudin, Patrick Marcellin, M Pouteau, Jean-pierre Benhamou, Nicole Colas-linhart, Jean‐pierre Le Floch, Catherine Lemmonier, B. Bok
    Abstract:

    Thyroid dysfunction has been reported as a complication of Interferon therapy. The aim of our study was to assess the risk factors and reversibility of thyroid disorders induced by Interferon therapy. Prospective study. A series of 68 patients with chronic hepatitis C completed a therapeutic trial of Interferon Alpha 2b (IFN), randomized for dose adaptation, lasting for 24 weeks. TSH and autoantibodies against thyroid were looked for at (-2) weeks and 24 weeks in all patients. Blood samples obtained at (-2), 12, and 24 weeks were stored for additional hormonal studies in patients who developed thyroid dysfunction. Such patients with thyroid dysfunction were followed up for at least one year. Only one out of 68 patients had abnormal TSH levels, and two had thyroid autoantibodies prior to Interferon therapy. Eight patients (12%) developed thyroid dysfunction (five hypothyroidism and three hyperthyroidism) during treatment. In four patients (all of them with thyroid dysfunction, P < 0.001) antimicrosomal, antithyroglobulin, and/or anti-TSH receptor antibodies appeared during Interferon therapy. All patients recovered normal thyroid function within 1.5 years after Interferon withdrawal. No pretreatment risk factor was identified. The patients with thyroid dysfunction did not significantly differ from the others as regards the dose of Interferon they received or the rate of normalization of transaminases. (i) A 12% incidence of thyroid dysfunction was observed under Interferon therapy; (ii) secondary appearance under Interferon therapy of elevated thyroid autoantibodies was a risk factor; (iii) the thyroid disorders induced by Interferon were reversible.

  • Recombinant Alpha Interferon for chronic hepatitis B in anti-HIV positive patients receiving zidovudine.
    Gut, 1993
    Co-Authors: Patrick Marcellin, N Boyer, J F Colin, M Martinot-peignoux, V Lefort, S Matheron, S Erlinger, Jean-pierre Benhamou
    Abstract:

    In this pilot study of the effects of Interferon alfa in 10 anti-HIV positive, chronic hepatitis B patients treated with zidovudine (AZT), tolerance to Interferon was good and similar to that in anti-HIV negative patients. After treatment, the HIV stage and CD4 lymphocyte count were unchanged. In two patients hepatitis B virus (HBV)-DNA and hepatitis B e antigen (HBeAg) disappeared and the serum alanine aminotransferase (ALT) returned to normal; loss of hepatitis B surface antigen (HBsAg) with absence of histopathological activity was observed after treatment in one of these patients. These preliminary results need to be confirmed by a larger study.

  • Sustained hypothyroidism induced by Recombinant Alpha Interferon in patients with chronic hepatitis C.
    Gut, 1992
    Co-Authors: Patrick Marcellin, M Pouteau, P. Renard, J M Grynblat, N Colas Linhart, P Bardet, B. Bok, Jean-pierre Benhamou
    Abstract:

    Thyroid dysfunction has been reported in patients with malignant disease treated with Recombinant Alpha Interferon. Two cases of hypothyroidism in patients with chronic hepatitis C treated with Recombinant Alpha Interferon are reported. In one patient, Interferon induced hypothyroidism in the absence of pre-existing thyroid dysfunction and in the other it aggravated a pre-existing thyroid dysfunction. Both patients developed a severe, sustained hypothyroidism requiring thyroxine treatment for one year or more after stopping Alpha Interferon. Diagnosis of hypothyroidism during treatment can be difficult because of the common side effects of Alpha Interferon. Thyroid function should be assessed before and during Alpha Interferon therapy in patients with chronic hepatitis C.

M Pouteau - One of the best experts on this subject based on the ideXlab platform.

  • reversibility of thyroid dysfunction induced by Recombinant Alpha Interferon in chronic hepatitis c
    Clinical Endocrinology, 1993
    Co-Authors: Eric Baudin, Patrick Marcellin, M Pouteau, Jean-pierre Benhamou, Catherine Lemmonier, Nicole Colaslinhart, Jeanpierre Le Floch, B. Bok
    Abstract:

    Summary OBJECTIVE Thyroid dysfunction has been reported as a complication of Interferon therapy. The aim of our study was to assess the risk factors and reversibility of thyroid disorders induced by Interferon therapy. DESIGN Prospective study. PATIENTS A series of 68 patients with chronic hepatitis C completed a therapeutic trial of Interferon Alpha 2b (IFN), randomized for dose adaptation, lasting for 24 weeks. MEASUREMENTS TSH and autoantibodies against thyroid were looked for at (- 2) weeks and 24 weeks in all patients. Blood samples obtained at (-2), 12, and 24 weeks were stored for additional hormonal studies in patients who developed thyroid dysfunction. Such patients with thyroid dysfunction were followed up for at least one year. RESULTS Only one out of 68 patients had abnormal TSH levels, and two had thyroid autoantibodies prior to Interferon therapy. Eight patients (12%) developed thyroid dysfunction (five hypothyroidism and three hyperthyroidism) during treatment. In four patients (all of them with thyroid dysfunction, P< 0-001) antimicrosomal, antithyro-globulin, and/or anti-TSH receptor antibodies appeared during Interferon therapy. All patients recovered normal thyroid function within 15 years after Interferon withdrawal. No pretreatment risk factor was identified. The patients with thyroid dysfunction did not significantly differ from the others as regards the dose of Interferon they received or the rate of normalization of transaminases. CONCLUSION (i) A 12% incidence of thyroid dysfunction was observed under Interferon therapy: (ii) secondary appearance under Interferon therapy of elevated thyroid autoantibodies was a risk factor; (iii) the thyroid disorders induced by Interferon were reversible.

  • Reversibility of thyroid dysfunction induced by Recombinant Alpha Interferon in chronic hepatitis C.
    Clinical endocrinology, 1993
    Co-Authors: Eric Baudin, Patrick Marcellin, M Pouteau, Jean-pierre Benhamou, Nicole Colas-linhart, Jean‐pierre Le Floch, Catherine Lemmonier, B. Bok
    Abstract:

    Thyroid dysfunction has been reported as a complication of Interferon therapy. The aim of our study was to assess the risk factors and reversibility of thyroid disorders induced by Interferon therapy. Prospective study. A series of 68 patients with chronic hepatitis C completed a therapeutic trial of Interferon Alpha 2b (IFN), randomized for dose adaptation, lasting for 24 weeks. TSH and autoantibodies against thyroid were looked for at (-2) weeks and 24 weeks in all patients. Blood samples obtained at (-2), 12, and 24 weeks were stored for additional hormonal studies in patients who developed thyroid dysfunction. Such patients with thyroid dysfunction were followed up for at least one year. Only one out of 68 patients had abnormal TSH levels, and two had thyroid autoantibodies prior to Interferon therapy. Eight patients (12%) developed thyroid dysfunction (five hypothyroidism and three hyperthyroidism) during treatment. In four patients (all of them with thyroid dysfunction, P < 0.001) antimicrosomal, antithyroglobulin, and/or anti-TSH receptor antibodies appeared during Interferon therapy. All patients recovered normal thyroid function within 1.5 years after Interferon withdrawal. No pretreatment risk factor was identified. The patients with thyroid dysfunction did not significantly differ from the others as regards the dose of Interferon they received or the rate of normalization of transaminases. (i) A 12% incidence of thyroid dysfunction was observed under Interferon therapy; (ii) secondary appearance under Interferon therapy of elevated thyroid autoantibodies was a risk factor; (iii) the thyroid disorders induced by Interferon were reversible.

  • Sustained hypothyroidism induced by Recombinant Alpha Interferon in patients with chronic hepatitis C.
    Gut, 1992
    Co-Authors: Patrick Marcellin, M Pouteau, P. Renard, J M Grynblat, N Colas Linhart, P Bardet, B. Bok, Jean-pierre Benhamou
    Abstract:

    Thyroid dysfunction has been reported in patients with malignant disease treated with Recombinant Alpha Interferon. Two cases of hypothyroidism in patients with chronic hepatitis C treated with Recombinant Alpha Interferon are reported. In one patient, Interferon induced hypothyroidism in the absence of pre-existing thyroid dysfunction and in the other it aggravated a pre-existing thyroid dysfunction. Both patients developed a severe, sustained hypothyroidism requiring thyroxine treatment for one year or more after stopping Alpha Interferon. Diagnosis of hypothyroidism during treatment can be difficult because of the common side effects of Alpha Interferon. Thyroid function should be assessed before and during Alpha Interferon therapy in patients with chronic hepatitis C.

Eric Baudin - One of the best experts on this subject based on the ideXlab platform.

  • reversibility of thyroid dysfunction induced by Recombinant Alpha Interferon in chronic hepatitis c
    Clinical Endocrinology, 1993
    Co-Authors: Eric Baudin, Patrick Marcellin, M Pouteau, Jean-pierre Benhamou, Catherine Lemmonier, Nicole Colaslinhart, Jeanpierre Le Floch, B. Bok
    Abstract:

    Summary OBJECTIVE Thyroid dysfunction has been reported as a complication of Interferon therapy. The aim of our study was to assess the risk factors and reversibility of thyroid disorders induced by Interferon therapy. DESIGN Prospective study. PATIENTS A series of 68 patients with chronic hepatitis C completed a therapeutic trial of Interferon Alpha 2b (IFN), randomized for dose adaptation, lasting for 24 weeks. MEASUREMENTS TSH and autoantibodies against thyroid were looked for at (- 2) weeks and 24 weeks in all patients. Blood samples obtained at (-2), 12, and 24 weeks were stored for additional hormonal studies in patients who developed thyroid dysfunction. Such patients with thyroid dysfunction were followed up for at least one year. RESULTS Only one out of 68 patients had abnormal TSH levels, and two had thyroid autoantibodies prior to Interferon therapy. Eight patients (12%) developed thyroid dysfunction (five hypothyroidism and three hyperthyroidism) during treatment. In four patients (all of them with thyroid dysfunction, P< 0-001) antimicrosomal, antithyro-globulin, and/or anti-TSH receptor antibodies appeared during Interferon therapy. All patients recovered normal thyroid function within 15 years after Interferon withdrawal. No pretreatment risk factor was identified. The patients with thyroid dysfunction did not significantly differ from the others as regards the dose of Interferon they received or the rate of normalization of transaminases. CONCLUSION (i) A 12% incidence of thyroid dysfunction was observed under Interferon therapy: (ii) secondary appearance under Interferon therapy of elevated thyroid autoantibodies was a risk factor; (iii) the thyroid disorders induced by Interferon were reversible.

  • Reversibility of thyroid dysfunction induced by Recombinant Alpha Interferon in chronic hepatitis C.
    Clinical endocrinology, 1993
    Co-Authors: Eric Baudin, Patrick Marcellin, M Pouteau, Jean-pierre Benhamou, Nicole Colas-linhart, Jean‐pierre Le Floch, Catherine Lemmonier, B. Bok
    Abstract:

    Thyroid dysfunction has been reported as a complication of Interferon therapy. The aim of our study was to assess the risk factors and reversibility of thyroid disorders induced by Interferon therapy. Prospective study. A series of 68 patients with chronic hepatitis C completed a therapeutic trial of Interferon Alpha 2b (IFN), randomized for dose adaptation, lasting for 24 weeks. TSH and autoantibodies against thyroid were looked for at (-2) weeks and 24 weeks in all patients. Blood samples obtained at (-2), 12, and 24 weeks were stored for additional hormonal studies in patients who developed thyroid dysfunction. Such patients with thyroid dysfunction were followed up for at least one year. Only one out of 68 patients had abnormal TSH levels, and two had thyroid autoantibodies prior to Interferon therapy. Eight patients (12%) developed thyroid dysfunction (five hypothyroidism and three hyperthyroidism) during treatment. In four patients (all of them with thyroid dysfunction, P < 0.001) antimicrosomal, antithyroglobulin, and/or anti-TSH receptor antibodies appeared during Interferon therapy. All patients recovered normal thyroid function within 1.5 years after Interferon withdrawal. No pretreatment risk factor was identified. The patients with thyroid dysfunction did not significantly differ from the others as regards the dose of Interferon they received or the rate of normalization of transaminases. (i) A 12% incidence of thyroid dysfunction was observed under Interferon therapy; (ii) secondary appearance under Interferon therapy of elevated thyroid autoantibodies was a risk factor; (iii) the thyroid disorders induced by Interferon were reversible.